Background: Most of the previous studies that explored the molecular basis of raltegravir resistance were conducted studying the HIV-1 B subtype. It has been shown that the CRF02_AG subtype in relation to its natural integrase (IN) sequence could develop different genetic pathways associated with raltegravir resistance. The aim of this study was to explore resistance pathways preferably used by CRF02_AG viruses compared with subtype B.
HIV-1-resistant variants generated with first-generation compounds. In vitro, serial passage experiments using wild-type clinical isolates in the presence of continued dolutegravir or MK-2048 pressure led to the selection of single or combined amino acid substitutions, including L101I, T124A and S153Y/F mutations for dolutegravir, 1 and two amino acid substitutions, G118R and E138K, for MK-2048. 2 Most of the data about the efficacy and failure of INIs concerns HIV-1 subtype B, whereas these data are missing for the CRF02_AG subtype, which is highly prevalent in West Africa, and becoming, in recent years, more common in developed countries.
3 Because variations at the nucleotide level could have the ability to drive the resistance escape pathway, there is a need for additional data for the CRF02_AG subtype. 4 The aim of this study was to explore all the IN mutations previously described in subtype B as involved in resistance to firstgeneration (raltegravir and elvitegravir) and second-generation (dolutegravir and MK-2048) INIs in 25 patients infected with the HIV-1 CRF02_AG subtype and failing a raltegravir-containing regimen.
Methods
Twenty-five HIV-1-infected patients failing to respond to 400 mg of raltegravir (two consecutive viral loads .200 copies/mL) administered twice daily, all infected with CRF02_AG subtype, were studied retrospectively. Plasma samples were collected in three clinical centres in Paris, France (Pitié-Salpêtrière, Bichat-Claude Bernard and Saint-Antoine hospitals), and one in Rome, Italy (Department of Experimental Medicine, University of Rome 'Tor Vergata'). Viral RNA was extracted from plasma and the complete nucleotide sequences of the IN coding region were amplified and sequenced as previously described. 5 Sequences were then analysed, using CodonCode Aligner software, for the presence, in 20 positions, of previously described in vivo and/or in vitro mutations against first-and second-generation INIs: T66A/I/K, V72I, L74M, E92Q, T97A, F121Y, E138A/K, G140A/S, Y143C/H/R, S147G, Q148C/E/H/K/R, V151I, S153Y, N155H/S, E157Q, G163R and S230R for raltegravir/elvitegravir; L101I, T124A and S153F/Y for dolutegravir; and G118R and E138K for MK-2048.
Phenotypic susceptibility of the viral isolates was assessed by means of a recombinant virus assay, as described previously. 6 Briefly, viral RNA was extracted and cDNA prepared. The RT-RNAseH-IN region was amplified. The RT-IN amplicons were recombined into an HxB2D backbone lacking the RT-IN region (pHXB2D-RT-IN-eGFP). Replication-competent recombinant viruses were titrated and subjected to an antiviral experiment in serial dilutions of raltegravir and elvitegravir using MT4-LTR-eGFP cells. Fold changes in IC 50 values using the wild-type HIV-1 IIIB as the reference virus were calculated. Viruses were considered resistant when the fold change value was greater than the biological test cut-off (2.0 and 1.9 for raltegravir and elvitegravir, respectively).
Results
Twenty-five HIV-1-infected patients failing raltegravir and infected with the CRF02_AG subtype were retrospectively studied. The median plasma HIV-1 RNA level at failure was 4.5 log 10 copies/mL (range 1.4 -5.4 log 10 copies/mL) and the time on raltegravir therapy until failure was, on average, 13 months (range 4 -25 months). The complete nucleotide sequences of the IN coding region were determined for clinical isolates obtained from patients at raltegravir failure. The sequence analysis showed the presence of several residues among the 13 previously described as specific for the CRF02_AG subtype (14R, 31I, 101I, 112V/I, 124A, 125A, 134N, 135V, 136T/Q, 201I, 206S, 234I and 283G) (data not shown). 7 The analysis of the 20 residues implicated in resistance to raltegravir, elvitegravir, dolutegravir and MK-2048 showed that six IN residues (66, 121, 147, 151, 153 and 230) did not show any mutation in all sequences, whereas three positions (72, 101 and 124) were frequently mutated. The 101I and 124A mutations, selected in vitro by dolutegravir, were present, alone or together, in all sequences (20 sequences with 101I+ 124A, 3 sequences with 101I and 2 sequences with 124A). On the other hand, the 72I mutation was present in 18 sequences (72%). This mutation was previously reported as a frequent polymorphic mutation in INI-naive patients (60% in subtype CRF02_AG and 55% in subtype B), 7 but also as a minor raltegravir resistance mutation. With the exception of these frequent mutated residues, it was observed that 7 sequences (28%) in patients p1 -p7 harboured major raltegravir resistance-associated mutations (Table 1) , whereas 18 sequences (72%) showed a lack of major mutations. Thus the 155H mutation, associated with 92Q, 97A or 157Q + 163R, was detected in four patients, the 143R mutation, associated with 138A, was detected in one patient and the 157Q mutation alone was detected in one patient. One patient showed a mixed resistance profile with mutations 143C/H/R and 148R associated with three other mutations; 138K, 140A and 163R (Table 1 ). Among the 18 remaining patients, 1 patient (p8) showed an unusual association of two INI resistance-associated mutations, 74M and 118R (Table 1) , the first known as a minor mutation associated with raltegravir resistance and the second one being a mutation only linked thus far to MK-2048 and S-1360 derivative resistance. 8 The 74M + 118R profile, never described before as a resistance profile to raltegravir/elvitegravir, was further investigated. The different characteristics of the patient harbouring this 
profile are detailed in Table 2 . The HIV-1 load decreased from baseline to become undetectable (,40 copies/mL) in 3 months after raltegravir treatment and then returned to a value close to that of baseline at month 17 while still receiving raltegravir. The comparison of IN sequences between initiation of raltegravir treatment (day 0) and failure of raltegravir (month 17) showed the appearance of the single G118R mutation, which confers a high level of resistance to raltegravir (from 1-to 25.5-fold change at failure compared with baseline) and to elvitegravir (from 2.8-to 9.2-fold change).
Discussion
INI resistance mutations described in vivo and/or in vitro have been mostly studied for HIV-1 subtype B. Nevertheless, the selection of resistance mutations could be influenced by the naturally occurring variations between the different non-B subtypes. 4, 7, 9 In this study, 25 HIV-1 IN sequences isolated from subtype CRF02_AG raltegravir-failing patients were analysed at the level of 20 amino acid positions previously described as involved in resistance to first-and second-generation INIs (raltegravir/elvitegravir and dolutegravir/MK-2048, respectively).
Our sequence analysis showed the presence of previously described major resistance mutations to raltegravir/elvitegravir associated with the 155 and 143 genetic pathways clearly established in five patients and one patient showed a 157Q mutation, previously described as linked to raltegravir failure. 5 In spite of the small number of patients showing resistance mutations to raltegravir, we confirmed the preferential use of the 155 pathway at failure in non-B subtypes, as previously described. 4, 9 The fact that many of the studied patients (72%) who experienced detectable viraemia while receiving raltegravir-based antiretroviral therapy lacked previously described major resistance mutations to raltegravir/elvitegravir is surprising, but this finding is concordant with results previously reported in a large European cohort study. 9 Further research is needed to fully elucidate this result by exploring the role of IN mutations, particularly in the non-B subtype, that are not currently recognized as major, and defining their possible implications for the use of first-as well as second-generation INIs.
In the p8 patient, the unusual association of 74M and 118R mutations was observed at failure. The presence of the G118R mutation was particularly interesting for several reasons. First, several studies have shown that the G118 amino acid residue was highly conserved across many HIV-1 subtypes. 7, 10 Second, this mutation has never been observed before in raltegravirfailing patients and has only been selected in cell cultures after a prolonged period with MK-2048 2 and an S-1360 derivative. 8 Furthermore, phenotypic analyses showed that the appearance of the single G118R mutation conferred a high level of resistance to raltegravir and elvitegravir. These results are concordant with another in vitro study showing increased fold changes to raltegravir and elvitegravir in the presence of a G118R mutation (7.2 and 2.6, respectively). 8 Greater increases in fold change could be explained in our patient by the presence in the L74M mutation, already present at baseline, before raltegravir treatment. Indeed, it has been shown that the presence of this mutation, previously reported in raltegravir failure, improved raltegravir resistance when it was added to N155H or T66K Raltegravir resistance in the CRF02_AG HIV-1 subtype mutations, resulting in an increased fold change from 16 to 37 and 9.6 to 40, respectively. 8 In conclusion, a genetic pathway including the G118R and L74M mutations has been described in resistance to raltegravir in the context of a CRF02_AG subtype virus. This particular combination of mutations should be further evaluated for phenotypic susceptibility to second-generation INIs, i.e. dolutegravir and MK-2048.
